Since the emerging and effective therapies are widely available, and in parallel to this survival of the cancer patients tends to increase, recently the skeletal metastases are more frequently seen. Skeletal metastases are observed in 20–85% of the patients, depending on cancer type. Prognosis after skeletal metastasis varies depending on tumor type and extent of the metastases. The average survival is limited to months in some cancer types while it may take years in other slowly progressing tumors such as breast, prostate, renal, and thyroid cancers. Regardless of the type of tumor, since skeletal metastases may cause severe pain, or lead to immobilization and pathological fractures, they severely affect the quality of life of cancer patients. In most patients, skeletal metastases are effectively treated by medical methods (chemotherapy, bisphosphonates, hormonal therapies, denosumab, and analgesics) and radiotherapy for palliation of pain. In patients who do not respond these standard palliative therapies, and also cannot tolerate open surgical procedures, minimally invasive thermal ablations, mainly radiofrequency and cryoablation offer alternatives. Moreover, chemotherapy and radiotherapy are preferred especially when it is seriously important to give an early start to primary treatments. In most cases, cement injection may be necessary after percutaneous ablation for trabecular microfractures to regain strength and stabilization.